Jefferies downgraded ImmunoGen to Hold from Buy with a price target of $31, up from $25, after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash. The firm sees no overlap from a Federal Trade Commission standpoint.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMGN: